• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Innoviva Inc (NQ: INVA )

    16.50 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 16.50
    Bid (Size) 12.46 (1)
    Ask (Size) 19.79 (1)
    Prev. Close 16.50
    Today's Range 16.50 - 16.50
    52wk Range 12.22 - 16.86
    Shares Outstanding 65,504,384
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
    Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries. 
    Via InvestorPlace
    Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
    Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
    Via Benzinga

    Performance

    YTD
    +0.79%
    +0.79%
    1 Month
    +3.77%
    +3.77%
    3 Month
    +8.48%
    +8.48%
    6 Month
    +0.79%
    +0.79%
    1 Year
    +30.02%
    +30.02%

    More News

    Read More
    Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    3 Under-$20 Stocks That Could Make You a Fortune
    Via InvestorPlace
    INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Innoviva to Participate in the BofA Securities Health Care Conference
    From Innoviva, Inc.
    Via Business Wire
    Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
    From Innoviva Specialty Therapeutics
    Via Business Wire
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
    Via InvestorPlace
    Chart Of The Day: Innoviva - Individual Investor Favorite
    Via Talk Markets
    Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
    From Innoviva Specialty Therapeutics
    Via Business Wire
    A Look Into Healthcare Sector Value Stocks
    Via Benzinga
    Innoviva to Participate in the Cantor Global Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
    From Innoviva, Inc.
    Via Business Wire
    Innoviva Appoints Stephen Basso as Chief Financial Officer
    From Innoviva, Inc.
    Via Business Wire
    Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Overview Of Value Stocks In The Healthcare Sector
    Via Benzinga
    Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
    Via InvestorPlace
    Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
    Via Benzinga
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
    From Innoviva, Inc.
    Via Business Wire
    Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.